Vraylar (cariprazine) is an atypical antipsychotic prescribed for schizophrenia, bipolar mania, bipolar depression, or as an add-on treatment for major depressive disorder in adults. It’s also ...

Vraylar may lead to mild side effects such as movement issues, restlessness, sleepiness, and weight gain, which are often temporary. Serious side effects may occur, including neuroleptic malignant ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...

Some people experience weight gain during treatment with Vraylar. While exercise may be helpful, it’s crucial not to overheat or dehydrate. Taking Vraylar can affect your metabolism, such as ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Vraylar can interact with several drugs, including certain antibiotics, antidepressants, and mood stabilizers, potentially increasing the risk of side effects or reducing Vraylar’s effectiveness. It’s ...

Allergan plcAGN, along with partner Gedeon Richter, announced positive top-line results from a second pivotal phase III study on its schizophrenia drug Vraylar. The study evaluated Vraylar ...

AbbVie ABBV announced that the FDA has approved Vraylar (cariprazine) for the adjunctive treatment of patients with major depressive disorder (MDD). Vraylar is presently approved for treating ...